Mutational analyses of multiple oncogenic pathways in intraductal papillary mucinous neoplasms of the pancreas

Pancreas

Volumn 36, Issue 2, 2008, Pages 168-172

  Schönleben, Frank ^a,b   Allendorf, John D ^c   Qiu, Wanglong ^a   Li, Xiaojun ^a   Ho, Daniel J ^a   Ciau, Nancy T ^c   Fine, Robert L ^a   Chabot, John A ^c   Remotti, Helen E ^c   Su, Gloria H ^a,c  

^a College of Physicians and Surgeons ^*  (United States)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c Department of Surgery ^*  (United States)

Author keywords

BRAF; EGFR; Her2; IPMN; KRAS; PIK3CA

Indexed keywords

ASPARAGINASE; B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GENOMIC DNA; PHOSPHATIDYLINOSITOL 3 KINASE; BRAF PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; ERBB2 PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PIK3CA PROTEIN, HUMAN; RAS PROTEIN;

ADULT; AGED; ARTICLE; CANCER INVASION; CARCINOGENICITY; CLINICAL ARTICLE; DNA EXTRACTION; DNA SEQUENCE; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENE TARGETING; HUMAN; HUMAN TISSUE; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; MALE; MUTATIONAL ANALYSIS; ONCOGENE NEU; PANCREAS CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TUMOR BIOPSY; TUMOR LOCALIZATION; CANCER STAGING; COHORT ANALYSIS; COLLOID CARCINOMA; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MUTATION; ONCOGENE; PAGET NIPPLE DISEASE; PANCREAS TUMOR; PATHOLOGY;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADENOCARCINOMA, MUCINOUS; AGED; AGED, 80 AND OVER; CARCINOMA, INTRADUCTAL, NONINFILTRATING; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; ONCOGENES; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 45549106185     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e318158a4d2     Document Type: Article

References (32)

1. Hruban RH, Takaori K, Klimstra DS, et al. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol. 2004;28:977-987.
2. Kloppel G, Solcia E, Longnecker DS. Histological Typing of Tumours of the Exocrine Pancreas. New York: Springer; 1996.
3. Raimondo M, Tachibana I, Urrutia R, et al. Invasive cancer and survival of intraductal papillary mucinous tumors of the pancreas. Am J Gastroenterol. 2002;97:2553-2558.
4. Maire F, Hammel P, Terris B, et al. Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma. Gut. 2002; 51:717-722.
5. Sohn TA, Yeo CJ, Cameron JL, et al. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg. 2004;239:788-797. [discussion 797-799].
6. Hermanova M, Lukas Z, Nenutil R, et al. Amplification and over expression of HER-2/neu in invasive ductal carcinomas of the pancreas and pancreatic intraepithelial neoplasms and the relationship to the expression of p21(WAF1/CIP1). Neoplasma. 2004;51:77-83.
7. Yamao K, Ohashi K, Nakamura T, et al. The prognosis of intraductal papillary mucinous tumors of the pancreas. Hepatogastroenterology. 2000;47:1129-1134.
8. Chari ST, Yadav D, Smyrk TC, et al. Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas. Gastroenterology. 2002;123:1500-1507.
9. Nakagohri T, Konishi M, Inoue K, et al. Invasive carcinoma derived from intraductal papillary mucinous carcinoma of the pancreas. Hepatogastroenterology. 2004;51:1480-1483.
10. Z'Graggen K, Rivera JA, Compton CC, et al. Prevalence of activating K-ras mutations in the evolutionary stages of neoplasia in intraductal papillary mucinous tumors of the pancreas. Ann Surg. 1997;226:491-498. [discussion 498-500].
11. Sessa F, Solcia E, Capella C, et al. Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: an investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients. Virchows Arch. 1994;425:357-367.
12. Sato N, Rosty C, Jansen M, et al. STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas. Am J Pathol. 2001;159:2017-2022.
13. Schonleben F, Qiu W, Ciau NT, et al. PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas. Clin Cancer Res. 2006;12:3851-3855.
14. Fujii H, Inagaki M, Kasai S, et al. Genetic progression and heterogeneity in intraductal papillary-mucinous neoplasms of the pancreas. Am J Pathol. 1997;151:1447-1454.
15. Moriya T, Kimura W, Semba S, et al. Biological similarities and differences between pancreatic intraepithelial neoplasias and intraductal papillary mucinous neoplasms. Int J Gastrointest Cancer. 2005;35: 111-119.
16. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350:2129-2139.
17. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-1500.
18. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from Bnever smokers[ and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004;101:13306-13311.
19. Shigematsu H, Takahashi T, Nomura M, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. 2005;65:1642-1646.
20. Stephens P, Hunter C, Bignell G, et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature. 2004;431:525-526.
21. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954.
22. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304:554.
23. Schonleben F, Qiu W, Bruckman KC, et al. BRAF and KRAS gene mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/IPMC) of the pancreas. Cancer Lett. 2006;8:8.
24. Lee JW, Soung YH, Kim SY, et al. ERBB2 kinase domain mutation in a gastric cancer metastasis. Apmis. 2005;113:683-687.
25. Satoh K, Shimosegawa T, Moriizumi S, et al. K-ras mutation and p53 protein accumulation in intraductal mucin-hypersecreting neoplasms of the pancreas. Pancreas. 1996;12:362-368.
26. Moskaluk CA, Hruban RH, Kern SE. p16 and K-ras mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res. 1997;57:2140-2143.
27. Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002;62: 6997-7000.
28. Yuen ST, Davies H, Chan TL, et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res. 2002;62:6451-6455.
29. Qiu W, Schonleben F, Li X, et al. PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res. 2006;12: 1441-1446.
30. Ikenoue T, Kanai F, Hikiba Y, et al. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res. 2005;65: 4562-4567.
31. Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A. 2005;102:802-807.
32. Gallmeier E, Calhoun ES, Kern SE. No mutations in PIK3CA identified in pancreatic carcinoma. NOGO. 2004;8:2.